From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“已获批准、指定、列入、合格、注册、报销或预先授权的选择”,从而进入买方的采购、报销、处方集、规格、采购、网络、目录或计划系统,使未来业务无需每次单独销售即可获得,并且管理层表示这种准入状态是新的,大部分量尚未反映在报告结果中。 在记录中,管理层讨论了与Aetna的合并、PBM业务、零售业务等。关于准入状态,有提到“preferred pharmacy in various Medicare Part D networks”(在多个Medicare Part D网络中的首选药房),以及“partnerships with PBMs and health plans across the industry”(与行业内的PBM和健康计划的合作)。但这是否是“最近”的转变?管理层提到“our expanded participation as a preferred pharmacy in various Medicare Part D networks”(我们在多个Medicare Part D网络中扩大参与作为首选药房),这暗示了最近的变化。此外,Dave Denton提到“we are seeing a greater benefit from the broader relationships we established last year with payers as well as from our expanded participation as a preferred pharmacy in various Medicare Part D networks.”(我们看到了去年与支付方建立的更广泛关系以及我们在多个Medicare Part D网络中扩大参与作为首选药房带来的更大好处。)这表明这些关系是最近建立的,并且正在带来好处。 然而,管理层是否明确表示这种准入状态是新的,并且大部分量尚未反映在结果中?Dave Denton说:“We are seeing a greater benefit from the broader relationships we established last year with payers as well as from our expanded participation as a preferred pharmacy in various Medicare Part D networks.”(我们看到了去年与支付方建立的更广泛关系以及我们在多个Medicare Part D网络中扩大参与作为首选药房带来的更大好处。)这暗示了这些关系是最近建立的,并且正在带来好处,但并未明确说“大部分量尚未反映”。此外,在讨论2019年销售季时,Jon Roberts提到“we are more than halfway through our 2019 renewals”(我们已过半2019年续约),但这是关于续约,不是新的准入。 关于“preferred pharmacy”地位,这确实是一种准入状态,但管理层是否说这是“最近”的?他们提到“expanded participation”,表明是扩大,但可能不是全新的。另外,在零售业务中,他们提到“partnerships with PBMs and health plans across the industry”,但这是普通合作关系。 关键点:管理层是否描述了公司从“候选”变为“默认”的转变?他们提到了“preferred pharmacy”地位,这确实是一种准入,但并未明确说这是新的,并且大部分量尚未反映。他们提到“we are seeing a greater benefit”,表明已经开始受益,但未说“大部分量尚未反映”。 此外,关于Aetna交易,那是待定的,不是已完成的准入。 因此,我认为没有明确描述这一现象。答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.